CompoAtlas

L-Lysine

Food supplement declared in France, declaration No 2023-6-1076, decision dated 21 June 2023

L-Lysine (BiotechUSA) is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition.

Brand
BiotechUSA
Food business operator placing the product on the market
BioTechUSA Kft.
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
3x1 gélule par jour
Not recommended (according to the manufacturer)
Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Taking medication
Objectives stated by the manufacturer (these are not authorised claims)
Sport

Declaration 196702, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Other active ingredients

NamePer day
Chlorhydrate de lysinenot declared

Additives

E470b

Other ingredients

gélatine

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Other declarations with the same name

This name is used by more than 10 declarations from different companies, so it does not identify one product. See every declaration with this name.

Brand : BiotechUSA

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2023. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line